【中金：维持欧康维视生物-B(01477.HK)跑赢行业评级 上调目标价至10.16港元】智通财经APP获悉，中金发布研报称，维持欧康维视生物-B(01477.HK)2025年/2026年的盈利预测。该行维持跑赢行业评级，考虑到近期板块估值中枢上移，该行上调基于DCF目标价35.5%至10.16港元，较当前股价有3.4%的上行空间。公司公布2025年上半年业绩：收入2.94亿元，同比增长75.4%;期内亏损1.32亿元，对比2024年同期收窄，符合该行预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.